On a disclosed annual basis, sales were KRW 1.02 billion in 2022, KRW 1.12 billion in 2023 (up 10.2% year on year), KRW 1.93 billion in 2024 (up 72.1%) and KRW 1.95 billion in 2025 (up 0.8%). Sales rose three years in a row from 2023 through 2025, but the 2025 gain of 0.8% left top-line growth nearly flat.
Over the same period the operating loss was KRW 8.3 billion in 2022, KRW 8.71 billion in 2023, KRW 9.33 billion in 2024 and KRW 10.9 billion in 2025, a loss in each of four years with the size growing every year.
The operating margin improved from -813.6% in 2022 to -482.3% in 2024 before slipping back to -556.8% in 2025. The net loss attributable to controlling shareholders was KRW 10.9 billion in 2025, and the consolidated net loss including non-controlling interests was also KRW 10.9 billion.
The debt ratio moved widely, from 82.8% in 2022 to 339.2% in 2023, 85.2% in 2024 and 120.2% in 2025. At the end of 2025 total equity was KRW 7.14 billion and total liabilities were KRW 8.58 billion. Operating cash flow went from negative KRW 7.3 billion in 2022 to negative KRW 9.5 billion in 2025.
Media reports attributed the flat 2025 sales to delays in research schedules at major cell therapy customers.
On a quarterly basis, sales rose from KRW 335 million in the third quarter of 2025 to KRW 1.06 billion in the fourth quarter (up 217.8% from the prior quarter), then moved to KRW 1.02 billion in the first quarter of 2026, KRW 1.94 billion in the second and KRW 1.06 billion in the third.
The operating loss widened from KRW 2.38 billion in the third quarter of 2025 to KRW 3.26 billion in the fourth, then ran at KRW 2.91 billion, KRW 2.75 billion and KRW 2.98 billion through the third quarter of 2026.
Even in the second quarter of 2026, the strongest sales quarter, the operating loss was KRW 2.75 billion, so higher sales did not translate into a smaller loss. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 12.1 billion. A rights offering of KRW 9.5 billion to existing shareholders was carried out in November 2025.